Cremophor EL

Hans Gelderblom(Leiden University Medical Center), Alex Sparreboom(The Ohio State University), Kees Nooter(Rotterdam University of Applied Sciences), Jaap Verweij(Deutz (Germany))

European Journal of Cancer

September 1, 2001

10.1016/s0959-8049(01)00171-x

Cited by 1,637

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

|The Lancet|2012|2.1k

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

|The Lancet Oncology|2014|1.2k

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

|Annals of Oncology|2021|978